Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company that leverages our AI-based PLEOTHERAPY™ platform to develop novel first-in-class therapies for orphan and common diseases with unmet medical needs. Committed to treating severe chronic conditions through the development of innovative, first-in-class therapies. Utilizing the AI-based PLEOTHERAPY™ platform technology to discover, develop, and deliver breakthrough treatments to patients. These therapies consist of reformulated or new chemical entity (NCE) drug combinations with potentially high reward/high risk ratios and accelerated/cost-effective development pathways.